Flagship Pioneering, firm behind Moderna vaccine, re-opens Fund VII

The firm now plans to consolidate its two different fund series and is targeting $3bn in total commitments for Fund VII, according to MassPrim.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this